Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 1, 2010, Pages 39-48

  Ikeda, Tetsuya ^a   Nakamura, Kazufumi ^a   Akagi, Satoshi ^a   Kusano, Kengo Fukushima ^a   Matsubara, Hiromi ^b   Fujio, Hideki ^a   Ogawa, Aiko ^a   Miura, Aya ^a   Miura, Daiji ^a   Oto, Takahiro ^c   Yamanaka, Ryutaro ^a   Otsuka, Fumio ^a   Date, Hiroshi ^d   Ohe, Tohru ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c Departments of Cancer and Thoracic Surgery

^d KYOTO UNIVERSITY   (Japan)

Author keywords

PDGF; Pulmonary hypertension; Smooth muscle cells; Statin

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PROTEIN P27; SIMVASTATIN;

ADOLESCENT; ADULT; ARTICLE; CELL ACTIVITY; CELL CYCLE; CELL GROWTH; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DNA SYNTHESIS; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; IMMUNOFLUORESCENCE TEST; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; CELL MOVEMENT; CELL PROLIFERATION; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PULMONARY ARTERY; SIGNAL TRANSDUCTION; SIMVASTATIN; YOUNG ADULT;

EID: 75749156242     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181c0419c     Document Type: Article

References (35)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111-117.
2. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-1206.
3. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115: 2811-2821.
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
5. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
6. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106: 1477-1482.
7. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-249.
8. Negre-Aminou P, van Vliet AK, van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta. 1997;1345:259-268.
9. Porter KE, Naik J, Turner NA, et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002;36:150-157.
10. Corpataux JM, Naik J, Porter KE, et al. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res. 2005;129:52-56.
11. Ogawa A, Nakamura K, Matsubara H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation. 2005;112: 1806-1812.
12. Takeda M, Otsuka F, Nakamura K, et al. Characterization of the bone morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells isolated from a sporadic case of primary pulmonary hypertension: roles of BMP type IB receptor (activin receptor-like kinase-6) in the mitotic action. Endocrinology. 2004;145:4344-4354.
13. Fujio H, Nakamura K, Matsubara H, et al. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2006;47:250-255.
14. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-1413. (Pubitemid 41362714)
15. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005;115:2691-2694.
16. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
17. Negre-Aminou P, van Erck M, van Leeuwen RE, et al. Differential effect of simvastatin on various signal transduction intermediates in cultured human smooth muscle cells. Biochem Pharmacol. 2001;61:991-998.
18. Date H, Kusano KF, Matsubara H, et al. Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy. J Am Coll Cardiol. 2007;50:523-527.
19. Nakamura K, Shimizu J, Kataoka N, et al. Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. In press.
20. Kouchi H, Nakamura K, Fushimi K, et al. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;264:915-920.
21. Miura R, Nakamura K, Miura D, et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Sci. 2006;102:288-295. (Pubitemid 44790690)
22. Miyoshi T, Otsuka F, Suzuki J, et al. Mutual regulation of folliclestimulating hormone signaling and bone morphogenetic protein system in human granulosa cells. Biol Reprod. 2006;74:1073-1082.
23. Takahashi M, Otsuka F, Miyoshi T, et al. Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol. 2008;199:445-455.
24. Yoshikawa M, Nakamura K, Nagase S, et al. Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis. J Cardiovasc Pharmacol. 2009;53:179-186.
25. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107: 216-223. (Pubitemid 17137857)
26. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000;26:81-84.
27. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67: 737-744.
28. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002;166:1403-1408.
29. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108:1640-1645.
30. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest. 2005;127:1446-1452.
31. Sindermann JR, Fan L, Weigel KA, et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis. 2000;150:331-341.
32. Turner NA, O'Regan DJ, Ball SG, et al. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005;19:804-806.
33. Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001;104:790-795.
34. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105: 1672-1678.
35. Kimura S, Egashira K, Nakano K, et al. Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation. 2008;118:S65-S70